Skip to content

COrticosteroids in acUte uRticAria in emerGency dEpartment

COrticosteroids in acUte uRticAria in emerGency dEpartment

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03545464
Acronym
COURAGE
Enrollment
137
Registered
2018-06-04
Start date
2019-09-21
Completion date
2025-09-17
Last updated
2025-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Angiœdema, Urticaria

Keywords

Acute urticaria

Brief summary

To demonstrate the non-inferiority of the efficacy of a single antihistamine in comparison with an association of antihistamine and corticosteroid in the treatment of acute urticaria in emergency departments

Detailed description

Acute urticaria (hives) is a common skin disease. The prevalence of acute urticaria in life is about 15 to 20% in the general population. It is responsible for a frequent use of emergency departments (ED). The usual treatment is based on early administration of an association of antihistamines and corticosteroid. The therapeutic efficacy of corticosteroids has never been established by high evidence studies. However, corticosteroids are frequently used. When stopped, corticosteroids could promote the occurence of urticaria recurrences, and a transition to chronic urticaria. In addition, corticosteroids may be rarely responsible for gastrointestinal bleeding, hypertension and diabetes.

Interventions

Levocetirizine Oral Tablet 5 mg

DRUGPlacebo Oral Tablet

Placebo of cortancyl Oral Tablet 20mg

DRUGCortancyl Oral Tablet

Cortancyl oral Tablet 20 mg

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age \> 18 years * Isolated acute urticaria (acute hives): spontaneous urticaria, inducible urticaria * Acute urticaria with angioedema without laryngeal edema * Obtain patient's consent * Social security affiliation

Exclusion criteria

* Pregnancy or breastfeeding * Acute hives with anaphylaxis * Bradykinin angioedema * Angioedema without urticaria (hives) * Laryngeal edema with urticaria (hives) * Corticosteroid administration in the previous 5 days visiting the emergency department * Antihistamines greater than 1 tablet per day in the previous 5 days visiting the ED * Other treatment for urticaria : omalizumab, montelukast, ciclosporin A * Chronic urticaria before acute urticaria diagnosis * Atopic dermatitis * Eczema * Bullous pemphigoid * Acute exanthematous pustulosis * Diabetes mellitus * Gastrointestinal ulcer * Refusal to participate * Known allergy to the study drugs or formulation ingredients * Known Renal failure defined by creatinine clearance \< 10 mL/min or cardiac failure defined by ejection fraction \< 40%. * Corticoid use in 5 days prior to randomisation * Contra-indication to corticotherapy: * Any live vaccine * Psychotic states still uncontrolled by treatment limiting the participant's compliance with the research

Design outcomes

Primary

MeasureTime frameDescription
7-Days Urticaria Activity Score (UAS 7) at day 7For 7 dayUrticaria Activity Score (UAS) is a daily combined score of severity of itch and number of hives. Each component of the UAS is scored on a scale of 0 to 3; the 2 scores are added together for a daily total of 0 to 6.

Secondary

MeasureTime frameDescription
Occurrence of spontaneous wheals and/or itch for > 6 weeksbeyond 6 Weekswheals and/or itch for \> 6 weeks
Patients with angioedema at day 7, 14 and 3 monthsup to 3 monthangioedema
Recurrence of hives at day 7 and/or recurrence of itch at day 7For 7 dayThe UAS 7 is the sum of the daily UAS scores over 7 days. This questionnaire will be completed by the patient and the investigator.
(DLQI) up to 6 monthsup to 6 monthsThe DLQI is a dermatology-specific quality of life questionnaire designed for use in patients over 16 years of age
Cu-Q2QoL up to 6 monthsat day 7, at day 14, at 6 week, at 3 months and 6 monthsThe CU-Q2oL (French version) is a questionnaire that measures the relative burden of chronic urticaria on subjective well-being
The reduction of morbidity is assessed by new emergency visits for acute urticaria recurrences at day 7, 14 and 3 monthsup to 3 monthemergency visits

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026